Andreas Pinter

6.5k total citations · 2 hit papers
158 papers, 3.1k citations indexed

About

Andreas Pinter is a scholar working on Immunology, Dermatology and Physiology. According to data from OpenAlex, Andreas Pinter has authored 158 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Immunology, 101 papers in Dermatology and 27 papers in Physiology. Recurrent topics in Andreas Pinter's work include Psoriasis: Treatment and Pathogenesis (96 papers), Dermatology and Skin Diseases (86 papers) and Asthma and respiratory diseases (26 papers). Andreas Pinter is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (96 papers), Dermatology and Skin Diseases (86 papers) and Asthma and respiratory diseases (26 papers). Andreas Pinter collaborates with scholars based in Germany, United States and Canada. Andreas Pinter's co-authors include Kristian Reich, Diamant Thaçi, Andrew Blauvelt, Tsen‐Fang Tsai, Külli Kingo, M. Milutinovic, Sophie Hugot, Michael Ziv, F. Vanaclocha and R. You and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Andreas Pinter

137 papers receiving 3.0k citations

Hit Papers

Secukinumab is superior t... 2015 2026 2018 2022 2015 2021 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
    2015 429 citations Diamant Thaçi, Andrew Blauvelt et al. Journal of the American Academy of Dermatology profile →
  2. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
    2021 170 citations Andreas Pinter, Kristian Reich et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Andreas Pinter 2.2k 1.8k 527 516 421 158 3.1k
Howard Sofen 2.6k 1.2× 2.0k 1.1× 662 1.3× 656 1.3× 570 1.4× 96 3.9k
Caitriona Ryan 2.2k 1.0× 1.3k 0.7× 498 0.9× 404 0.8× 440 1.0× 55 3.1k
Sascha Gerdes 1.9k 0.8× 1.2k 0.6× 346 0.7× 301 0.6× 315 0.7× 116 2.5k
Michael Song 2.1k 0.9× 1.3k 0.7× 682 1.3× 450 0.9× 298 0.7× 49 2.5k
Robert Matheson 2.0k 0.9× 1.2k 0.7× 499 0.9× 417 0.8× 299 0.7× 20 2.7k
Angelo Ruggiero 1.0k 0.5× 893 0.5× 158 0.3× 263 0.5× 266 0.6× 101 1.6k
Marco Galluzzo 1.0k 0.5× 720 0.4× 212 0.4× 305 0.6× 207 0.5× 86 1.4k
Andrew Pink 661 0.3× 1.5k 0.8× 355 0.7× 483 0.9× 132 0.3× 89 2.0k
Stefan Jenisch 1.6k 0.7× 674 0.4× 345 0.7× 408 0.8× 169 0.4× 34 2.0k
Satveer K. Mahil 1.1k 0.5× 675 0.4× 179 0.3× 227 0.4× 178 0.4× 45 1.5k

Countries citing papers authored by Andreas Pinter

Since Specialization
Citations

This map shows the geographic impact of Andreas Pinter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Pinter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Pinter more than expected).

Fields of papers citing papers by Andreas Pinter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Pinter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Pinter. The network helps show where Andreas Pinter may publish in the future.

Co-authorship network of co-authors of Andreas Pinter

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Pinter. A scholar is included among the top collaborators of Andreas Pinter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Pinter. Andreas Pinter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Warren, Richard B., Mark Lebwohl, Diamant Thaçi, et al.. (2025). Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period. British Journal of Dermatology. 193(1). 44–55. 3 indexed citations
2.
Schäkel, Knut, Khusru Asadullah, Andreas Pinter, et al.. (2024). 50236 GUIDE trial results after withdrawal in part 3: Long-term remission in patients with psoriasis treated with guselkumab within 15 months from onset of symptoms. Journal of the American Academy of Dermatology. 91(3). AB222–AB222. 1 indexed citations
3.
Merola, Joseph F., Alice B. Gottlieb, Andreas Pinter, et al.. (2024). Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials. Dermatology and Therapy. 14(12). 3291–3306. 2 indexed citations
4.
Tada, Yayoi, Ahmed M. Soliman, Andreas Pinter, et al.. (2024). Dose escalation of biologic treatment in patients with moderate‐to‐severe psoriasis in Japan. Experimental Dermatology. 33(5). e15067–e15067. 1 indexed citations
5.
Gossec, Laure, Laura C. Coates, Dafna D. Gladman, et al.. (2024). Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial. Annals of the Rheumatic Diseases. 83(11). 1480–1488. 4 indexed citations
6.
Pinter, Andreas, Kilian Eyerich, Amy S. Paller, et al.. (2023). 77 JNJ-77242113 treatment induces strong systemic pharmacodynamic response versus placebo in patients with plaque psoriasis: Results from the phase 2, FRONTIER 1 study. Journal of Investigative Dermatology. 143(11). S345–S345. 1 indexed citations
7.
Tada, Yayoi, Ahmed M. Soliman, L. Puig, et al.. (2023). Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan. Dermatology and Therapy. 14(1). 99–114. 6 indexed citations
8.
Egeberg, Alexander, Andreas Pinter, Ronald Vender, et al.. (2023). 42592 Baseline Characteristics and Interim Month 12 mNAPSI Results in Patients with Moderate-to- Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics in the Psoriasis Study of Health Outcomes (PSoHO). Journal of the American Academy of Dermatology. 89(3). AB127–AB127. 1 indexed citations
9.
Leipe, Jan, Renate Schmelz, Gabriela Riemekasten, et al.. (2023). Chronische Entzündungserkrankungen in Deutschland. Zeitschrift für Rheumatologie. 83(3). 200–209. 3 indexed citations
10.
Ashtikar, Mukul, et al.. (2023). How wound environments trigger the release from Rifampicin-loaded liposomes. International Journal of Pharmaceutics. 633. 122606–122606. 6 indexed citations
11.
Reich, Kristian, Eric L. Simpson, Richard G. Langley, et al.. (2023). Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest. SKIN The Journal of Cutaneous Medicine. 7(2). s143–s143. 1 indexed citations
12.
13.
Maul, Lara Valeska, Christina Sorbe, Nikhil Yawalkar, et al.. (2023). Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT). Journal of the European Academy of Dermatology and Venereology. 38(4). 719–731. 6 indexed citations
14.
Reich, Adam, Andreas Pinter, Julia‐Tatjana Maul, et al.. (2023). Speed of clinical improvement in the real‐world setting from patient‐reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks. Journal of the European Academy of Dermatology and Venereology. 37(9). 1825–1840. 6 indexed citations
15.
Magnolo, Nina, Thomas Jaenicke, Athanasios Tsianakas, et al.. (2023). Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial. Journal of the European Academy of Dermatology and Venereology. 37(S5). 18–26. 11 indexed citations
16.
Schäkel, Knut, Kristian Reich, K. Asadullah, et al.. (2023). Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study. Journal of the European Academy of Dermatology and Venereology. 37(10). 2016–2027. 46 indexed citations
17.
Pinter, Andreas, Linda Stein Gold, Adam Reich, et al.. (2022). A novel, fixed‐dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30thEADV Congress 2021. Journal of the European Academy of Dermatology and Venereology. 37(S1). 14–19. 4 indexed citations
18.
Thaçi, Diamant, Kilian Eyerich, Andreas Pinter, et al.. (2021). Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. British Journal of Dermatology. 186(1). 30–39. 15 indexed citations
19.
Blauvelt, Andrew, C. Leonardi, Boni E. Elewski, et al.. (2020). A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*. British Journal of Dermatology. 184(6). 1047–1058. 73 indexed citations
20.
Pinter, Andreas, Dagmar Wilsmann‐Theis, Wiebke K. Peitsch, & Rotraut Mößner. (2019). Interleukin‐17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases. The Journal of Dermatology. 46(5). 426–430. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Howard Sofen Breakdown of academic impact, for papers by Caitriona Ryan Breakdown of academic impact, for papers by Sascha Gerdes Breakdown of academic impact, for papers by Michael Song Breakdown of academic impact, for papers by Robert Matheson Breakdown of academic impact, for papers by Angelo Ruggiero Breakdown of academic impact, for papers by Marco Galluzzo Breakdown of academic impact, for papers by Andrew Pink Breakdown of academic impact, for papers by Stefan Jenisch Breakdown of academic impact, for papers by Satveer K. Mahil
Rankless by CCL
2026